Company / Financials
Sonoma Pharmaceuticals, Inc. Financials
FY2011-FY2026 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$14.3M
FY2026 · +12.2% YoY
Net Income
-$3.5M
FY2026 · +28.5% YoY
Profit Margin
-24.2%
FY2026 · net income / revenue
ROE
-
FY2026 · return on equity
Total Assets
-
FY2026
Total Debt
-
FY2026
Equity
-
FY2026
ROA
-
FY2026 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$14.3M+12.2% YoYNet Income HistoryProfit after all expenses and taxes-$3.5M+28.5% YoYGross Profit HistoryRevenue minus cost of goods sold$5.5M+15.2% YoYCost of Revenue HistoryDirect costs of producing goods and services sold$8.8M+10.4% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$3.7M+21.1% YoYSG&A Expense HistorySelling, general, and administrative expenses$7.4M-2.8% YoYR&D Expense HistoryResearch and development spending$1.8M-3.0% YoYInterest Expense HistoryCost of borrowing and debt obligations-Income Tax HistoryTotal income tax expense$550.0K+380.6% YoYEPS (Basic) HistoryBasic earnings per share-$2.79+73.8% YoY